Skip to main content
Article
Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study
Annals of the Rheumatic Diseases (2017)
  • Matthew A Brown, Institute of Health and Biomedical Innovation
  • Paul A Bird, University of New South Wales
  • Philip C Robinson, Royal Brisbane and Women's Hospital
  • Philip J Mease, University of Washington
  • Filip van den Bosch, Ghent University Hospital
  • Christine Surian, Pfizer
  • Heather Jones, Pfizer
  • Annette Szumski, Pfizer
  • Lisa Marshall, Pfizer
  • Zirke Wiid
  • Maxime Dougados, Paris Descartes University
Publication Date
July 3, 2017
DOI
10.1136/annrheumdis-2017-211313
Citation Information
Matthew A Brown, Paul A Bird, Philip C Robinson, Philip J Mease, et al.. "Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study" Annals of the Rheumatic Diseases (2017)
Available at: http://works.bepress.com/philip-mease/38/